SCL/TAL1: A multifaceted regulator from blood development to disease

Blood

Volumn 129, Issue 15, 2017, Pages 2051-2060

  Porcher, Catherine ^a   Chagraoui, Hedia ^a   Kristiansen, Maiken S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN MYB; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR GATA; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR RUNX; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR TAL1; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; DNA BINDING PROTEIN; LIM PROTEIN; LMO1 PROTEIN, HUMAN; LMO2 PROTEIN, HUMAN; ONCOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TAL1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CELL DIFFERENTIATION; CELL FATE; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; DNA BINDING; ENDOCARDIUM; ENDOTHELIUM; GENE EXPRESSION; GENOME ANALYSIS; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMOGENESIS; MESODERMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR SURGERY; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LIM DOMAIN PROTEINS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTORS;

EID: 85018900318     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-12-754051     Document Type: Review

References (127)

1. Begley CG, Aplan PD, Davey MP, et al. Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. Proc Natl Acad Sci USA. 1989;86(6):2031-2035.
2. Shivdasani RA, Mayer EL, Orkin SH. Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. Nature. 1995; 373(6513):432-434.
3. Robb L, Lyons I, Li R, et al. Absence of yolk sac hematopoiesis from mice with a targeted disruption of the scl gene. Proc Natl Acad Sci USA. 1995;92(15):7075-7079.
4. Porcher C, Swat W, Rockwell K, Fujiwara Y, Alt FW, Orkin SH. The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. Cell. 1996;86(1):47-57.
5. Robb L, Elwood NJ, Elefanty AG, et al. The scl gene product is required for the generation of all hematopoietic lineages in the adult mouse. EMBO J. 1996;15(16):4123-4129.
6. McGrath KE, Frame JM, Fegan KH, et al. Distinct sources of hematopoietic progenitors emerge before HSCs and provide functional blood cells in the mammalian embryo. Cell Reports. 2015;11(12):1892-1904.
7. Ciau-Uitz A, Walmsley M, Patient R. Distinct origins of adult and embryonic blood in Xenopus. Cell. 2000;102(6):787-796.
8. Ciau-Uitz A, Monteiro R, Kirmizitas A, Patient R. Developmental hematopoiesis: ontogeny, genetic programming and conservation. Exp Hematol. 2014;42(8):669-683.
9. Kissa K, Herbomel P. Blood stem cells emerge from aortic endothelium by a novel type of cell transition. Nature. 2010;464(7285):112-115.
10. Boisset JC, van Cappellen W, Andrieu-Soler C, Galjart N, Dzierzak E, Robin C. In vivo imaging of haematopoietic cells emerging from the mouse aortic endothelium. Nature. 2010;464(7285): 116-120.
11. Padrón-Barthe L, Temiño S, Villa del Campo C, Carramolino L, Isern J, Torres M. Clonal analysis identifies hemogenic endothelium as the source of the blood-endothelial common lineage in the mouse embryo. Blood. 2014;124(16):2523-2532.
12. Swiers G, Rode C, Azzoni E, de Bruijn MF. A short history of hemogenic endothelium. Blood Cells Mol Dis. 2013;51(4):206-212.
13. Jordan HE. Evidence of hemogenic capacity of endothelium. Anat Rec. 1916;10:417-420.
14. Drake CJ, Brandt SJ, Trusk TC, Little CD. TAL1/SCL is expressed in endothelial progenitor cells/angioblasts and defines a dorsal-to-ventral gradient of vasculogenesis. Dev Biol. 1997; 192(1):17-30.
15. Drake CJ, Fleming PA. Vasculogenesis in the day 6.5 to 9.5 mouse embryo. Blood. 2000;95(5): 1671-1679.
16. Gering M, Rodaway AR, Göttgens B, Patient RK, Green AR. The SCL gene specifies haemangioblast development from early mesoderm. EMBO J. 1998;17(14):4029-4045.
17. Mead PE, Kelley CM, Hahn PS, Piedad O, Zon LI. SCL specifies hematopoietic mesoderm in Xenopus embryos. Development. 1998;125(14): 2611-2620.
18. D’Souza SL, Elefanty AG, Keller G. SCL/Tal-1 is essential for hematopoietic commitment of the hemangioblast but not for its development. Blood. 2005;105(10):3862-3870.
19. Lancrin C, Sroczynska P, Stephenson C, Allen T, Kouskoff V, Lacaud G. The haemangioblast generates haematopoietic cells through a haemogenic endothelium stage. Nature. 2009; 457(7231):892-895.
20. Schlaeger TM, Mikkola HK, Gekas C, Helgadottir HB, Orkin SH. Tie2Cre-mediated gene ablation defines the stem-cell leukemia gene (SCL/tal1)-dependent window during hematopoietic stem-cell development. Blood. 2005;105(10): 3871-3874.
21. Visvader JE, Fujiwara Y, Orkin SH. Unsuspected role for the T-cell leukemia protein SCL/tal-1 in vascular development. Genes Dev. 1998;12(4): 473-479.
22. Elefanty AG, Begley CG, Hartley L, Papaevangeliou B, Robb L. SCL expression in the mouse embryo detected with a targeted lacZ reporter gene demonstrates its localization to hematopoietic, vascular, and neural tissues. Blood. 1999;94(11):3754-3763.
23. Patterson LJ, Gering M, Patient R. Scl is required for dorsal aorta as well as blood formation in zebrafish embryos. Blood. 2005; 105(9):3502-3511.
24. Dooley KA, Davidson AJ, Zon LI. Zebrafish scl functions independently in hematopoietic and endothelial development. Dev Biol. 2005;277(2): 522-536.
25. Kinder SJ, Tsang TE, Quinlan GA, Hadjantonakis AK, Nagy A, Tam PP. The orderly allocation of mesodermal cells to the extraembryonic structures and the anteroposterior axis during gastrulation of the mouse embryo. Development. 1999;126(21): 4691-4701.
26. Lescroart F, Chabab S, Lin X, et al. Early lineage restriction in temporally distinct populations of Mesp1 progenitors during mammalian heart development. Nat Cell Biol. 2014;16(9):829-840.
27. Sabin FR. Preliminary note on the differentiation of angioblasts and the method by which they produce blood-vessels, blood-plasma and red blood-cells as seen in the living chick. 1917. J Hematother Stem Cell Res. 2002;11(1):5-7.
28. Murray PDF. The development in vitro of the blood of the early chick embryo. Proc R Soc Lond, B. 1932;111:497-520.
29. Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G. A common precursor for hematopoietic and endothelial cells. Development. 1998;125(4):725-732.
30. Huber TL, Kouskoff V, Fehling HJ, Palis J, Keller G. Haemangioblast commitment is initiated in the primitive streak of the mouse embryo. Nature. 2004;432(7017):625-630.
31. Gering M, Yamada Y, Rabbitts TH, Patient RK. Lmo2 and Scl/Tal1 convert non-axial mesoderm into haemangioblasts which differentiate into endothelial cells in the absence of Gata1. Development. 2003;130(25):6187-6199.
32. Schoenebeck JJ, Keegan BR, Yelon D. Vessel and blood specification override cardiac potential in anterior mesoderm. Dev Cell. 2007;13(2): 254-267.
33. Simões FC, Peterkin T, Patient R. Fgf differentially controls cross-antagonism between cardiac and haemangioblast regulators. Development. 2011;138(15):3235-3245.
34. Van Handel B, Montel-Hagen A, Sasidharan R, et al. Scl represses cardiomyogenesis in prospective hemogenic endothelium and endocardium. Cell. 2012;150(3):590-605.
35. Org T, Duan D, Ferrari R, et al. Scl binds to primed enhancers in mesoderm to regulate hematopoietic and cardiac fate divergence. EMBO J. 2015;34(6):759-777.
36. Bussmann J, Bakkers J, Schulte-Merker S. Early endocardial morphogenesis requires Scl/Tal1. PLoS Genet. 2007;3(8):e140.
37. Schumacher JA, Bloomekatz J, Garavito-Aguilar ZV, Yelon D. tal1 regulates the formation of intercellular junctions and the maintenance of identity in the endocardium. Dev Biol. 2013; 383(2):214-226.
38. Milgrom-Hoffman M, Harrelson Z, Ferrara N, Zelzer E, Evans SM, Tzahor E. The heart endocardium is derived from vascular endothelial progenitors. Development. 2011; 138(21):4777-4787.
39. Misfeldt AM, Boyle SC, Tompkins KL, Bautch VL, Labosky PA, Baldwin HS. Endocardial cells are a distinct endothelial lineage derived from Flk11 multipotent cardiovascular progenitors. Dev Biol. 2009;333(1):78-89.
40. Scialdone A, Tanaka Y, Jawaid W, et al. Resolving early mesoderm diversification through single-cell expression profiling. Nature. 2016;535(7611):289-293.
41. Lee D, Park C, Lee H, et al. ER71 acts downstream of BMP, Notch, and Wnt signaling in blood and vessel progenitor specification. Cell Stem Cell. 2008;2(5):497-507.
42. Kataoka H, Hayashi M, Nakagawa R, et al. Etv2/ ER71 induces vascular mesoderm from Flk11 PDGFRa1 primitive mesoderm. Blood. 2011; 118(26):6975-6986.
43. Rasmussen TL, Kweon J, Diekmann MA, et al. ER71 directs mesodermal fate decisions during embryogenesis. Development. 2011;138(21): 4801-4812.
44. Wareing S, Mazan A, Pearson S, Göttgens B, Lacaud G, Kouskoff V. The Flk1-Cre-mediated deletion of ETV2 defines its narrow temporal requirement during embryonic hematopoietic development. Stem Cells. 2012;30(7): 1521-1531.
45. Liu F, Kang I, Park C, et al. ER71 specifies Flk-11 hemangiogenic mesoderm by inhibiting cardiac mesoderm and Wnt signaling. Blood. 2012;119(14):3295-3305.
46. Singh BN, Kawakami Y, Akiyama R, et al. The Etv2-miR-130a network regulates mesodermal specification. Cell Reports. 2015;13(5):915-923.
47. Fujiwara Y, Chang AN, Williams AM, Orkin SH. Functional overlap of GATA-1 and GATA-2 in primitive hematopoietic development. Blood. 2004;103(2):583-585.
48. Hart A, Melet F, Grossfeld P, et al. Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity. 2000; 13(2):167-177.
49. Pimanda JE, Ottersbach K, Knezevic K, et al. Gata2, Fli1, and Scl form a recursively wired gene-regulatory circuit during early hematopoietic development. Proc Natl Acad Sci USA. 2007;104(45):17692-17697.
50. Faucon PC, Pardee K, Kumar RM, Li H, Loh YH, Wang X. Gene networks of fully connected triads with complete auto-activation enable multistability and stepwise stochastic transitions. PLoS One. 2014;9(7):e102873.
51. Ciau-Uitz A, Pinheiro P, Kirmizitas A, Zuo J, Patient R. VEGFA-dependent and -independent pathways synergise to drive Scl expression and initiate programming of the blood stem cell lineage in Xenopus. Development. 2013; 140(12):2632-2642.
52. Goode DK, Obier N, Vijayabaskar MS, et al. Dynamic gene regulatory networks drive hematopoietic specification and differentiation. Dev Cell. 2016;36(5):572-587.
53. Lichtinger M, Ingram R, Hannah R, et al. RUNX1 reshapes the epigenetic landscape at the onset of haematopoiesis. EMBO J. 2012;31(22): 4318-4333.
54. Adolfsson J, Månsson R, Buza-Vidas N, et al. Identification of Flt31 lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell. 2005;121(2):295-306.
55. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1(1):75-87.
56. Green AR, Lints T, Visvader J, Harvey R, Begley CG. SCL is coexpressed with GATA-1 in hemopoietic cells but is also expressed in developing brain [published correction appears in Oncogene. 1992;7(7):1459]. Oncogene. 1992; 7(4):653-660.
57. Mouthon MA, Bernard O, Mitjavila MT, Romeo PH, Vainchenker W, Mathieu-Mahul D. Expression of tal-1 and GATA-binding proteins during human hematopoiesis. Blood. 1993;81(3): 647-655.
58. de Graaf CA, Choi J, Baldwin TM, et al. Haemopedia: an expression atlas of murine hematopoietic cells. Stem Cell Rep. 2016;7(3): 571-582.
59. Mikkola HK, Klintman J, Yang H, et al. Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. Nature. 2003;421(6922):547-551.
60. Curtis DJ, Hall MA, Van Stekelenburg LJ, Robb L, Jane SM, Begley CG. SCL is required for normal function of short-term repopulating hematopoietic stem cells. Blood. 2004;103(9): 3342-3348.
61. Brunet de la Grange P, Armstrong F, Duval V, et al. Low SCL/TAL1 expression reveals its major role in adult hematopoietic myeloid progenitors and stem cells. Blood. 2006;108(9): 2998-3004.
62. Giroux S, Kaushik AL, Capron C, et al. lyl-1 and tal-1/scl, two genes encoding closely related bHLH transcription factors, display highly overlapping expression patterns during cardiovascular and hematopoietic ontogeny. Gene Expr Patterns. 2007;7(3):215-226.
63. Porcher C, Liao EC, Fujiwara Y, Zon LI, Orkin SH. Specification of hematopoietic and vascular development by the bHLH transcription factor SCL without direct DNA binding. Development. 1999;126(20):4603-4615.
64. Souroullas GP, Salmon JM, Sablitzky F, Curtis DJ, Goodell MA. Adult hematopoietic stem and progenitor cells require either Lyl1 or Scl for survival. Cell Stem Cell. 2009;4(2):180-186.
65. Lacombe J, Herblot S, Rojas-Sutterlin S, et al. Scl regulates the quiescence and the long-term competence of hematopoietic stem cells. Blood. 2010;115(4):792-803.
66. Lacombe J, Krosl G, Tremblay M, et al. Genetic interaction between Kit and Scl. Blood. 2013; 122(7):1150-1161.
67. Benyoucef A, Calvo J, Renou L, et al. The SCL/ TAL1 transcription factor represses the stress protein DDiT4/REDD1 in human hematopoietic stem/progenitor cells. Stem Cells. 2015;33(7): 2268-2279.
68. Lazrak M, Deleuze V, Noel D, et al. The bHLH TAL-1/SCL regulates endothelial cell migration and morphogenesis. J Cell Sci. 2004;117(Pt 7): 1161-1171.
69. Palii CG, Vulesevic B, Fraineau S, et al. Trichostatin A enhances vascular repair by injected human endothelial progenitors through increasing the expression of TAL1-dependent genes. Cell Stem Cell. 2014;14(5):644-657.
70. Hall MA, Curtis DJ, Metcalf D, et al. The critical regulator of embryonic hematopoiesis, SCL, is vital in the adult for megakaryopoiesis, erythropoiesis, and lineage choice in CFU-S12. Proc Natl Acad Sci USA. 2003;100(3):992-997.
71. Salmon JM, Slater NJ, Hall MA, et al. Aberrant mast-cell differentiation in mice lacking the stem-cell leukemia gene. Blood. 2007;110(10): 3573-3581.
72. Chagraoui H, Kassouf M, Banerjee S, et al. SCL-mediated regulation of the cell-cycle regulator p21 is critical for murine megakaryopoiesis. Blood. 2011;118(3):723-735.
73. Dey S, Curtis DJ, Jane SM, Brandt SJ. The TAL1/SCL transcription factor regulates cell cycle progression and proliferation in differentiating murine bone marrow monocyte precursors. Mol Cell Biol. 2010;30(9):2181-2192.
74. Goardon N, Lambert JA, Rodriguez P, et al. ETO2 coordinates cellular proliferation and differentiation during erythropoiesis. EMBO J. 2006;25(2):357-366.
75. Zeuner A, Eramo A, Testa U, et al. Control of erythroid cell production via caspase-mediated cleavage of transcription factor SCL/Tal-1. Cell Death Differ. 2003;10(8):905-913.
76. Kassouf MT, Hughes JR, Taylor S, et al. Genome-wide identification of TAL1’s functional targets: insights into its mechanisms of action in primary erythroid cells. Genome Res. 2010; 20(8):1064-1083.
77. Wu W, Morrissey CS, Keller CA, et al. Dynamic shifts in occupancy by TAL1 are guided by GATA factors and drive large-scale reprogramming of gene expression during hematopoiesis. Genome Res. 2014;24(12):1945-1962.
78. Massari ME, Murre C. Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol. 2000;20(2):429-440.
79. Tipping AJ, Pina C, Castor A, et al. High GATA-2 expression inhibits human hematopoietic stem and progenitor cell function by effects on cell cycle. Blood. 2009;113(12):2661-2672.
80. Fujiwara T, O’Geen H, Keles S, et al. Discovering hematopoietic mechanisms through genome-wide analysis of GATA factor chromatin occupancy. Mol Cell. 2009;36(4):667-681.
81. Wadman IA, Osada H, Grütz GG, et al. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J. 1997;16(11): 3145-3157.
82. Palii CG, Perez-Iratxeta C, Yao Z, et al. Differential genomic targeting of the transcription factor TAL1 in alternate haematopoietic lineages. EMBO J. 2011;30(3):494-509.
83. El Omari K, Hoosdally SJ, Tuladhar K, et al. Structural basis for LMO2-driven recruitment of the SCL:E47bHLH heterodimer to hematopoietic-specific transcriptional targets. Cell Reports. 2013;4(1):135-147.
84. Soler E, Andrieu-Soler C, de Boer E, et al. The genome-wide dynamics of the binding of Ldb1 complexes during erythroid differentiation. Genes Dev. 2010;24(3):277-289.
85. El Omari K, Hoosdally SJ, Tuladhar K, et al. Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex. Blood. 2011;117(7): 2146-2156.
86. Kassouf MT, Chagraoui H, Vyas P, Porcher C. Differential use of SCL/TAL-1 DNA-binding domain in developmental hematopoiesis. Blood. 2008;112(4):1056-1067.
87. Zhang J, Kalkum M, Yamamura S, Chait BT, Roeder RG. E protein silencing by the leukemogenic AML1-ETO fusion protein. Science. 2004;305(5688):1286-1289.
88. Krivega I, Dale RK, Dean A. Role of LDB1 in the transition from chromatin looping to transcription activation. Genes Dev. 2014;28(12):1278-1290.
89. Deng W, Lee J, Wang H, et al. Controlling long-range genomic interactions at a native locus by targeted tethering of a looping factor. Cell. 2012; 149(6):1233-1244.
90. Pimkin M, Kossenkov AV, Mishra T, et al. Divergent functions of hematopoietic transcription factors in lineage priming and differentiation during erythro-megakaryopoiesis. Genome Res. 2014;24(12):1932-1944.
91. Wilson NK, Foster SD, Wang X, et al. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell. 2010;7(4):532-544.
92. Wilson NK, Schoenfelder S, Hannah R, et al. Integrated genome-scale analysis of the transcriptional regulatory landscape in a blood stem/progenitor cell model. Blood. 2016;127(13): e12-e23.
93. Calkhoven CF, Muller C, Martin R, et al. Translational control of SCL-isoform expression in hematopoietic lineage choice. Genes Dev. 2003;17(8):959-964.
94. Batta K, Florkowska M, Kouskoff V, Lacaud G. Direct reprogramming of murine fibroblasts to hematopoietic progenitor cells. Cell Reports. 2014;9(5):1871-1884.
95. Capellera-Garcia S, Pulecio J, Dhulipala K, et al. Defining the minimal factors required for erythropoiesis through direct lineage conversion. Cell Reports. 2016;15(11):2550-2562.
96. Elcheva I, Brok-Volchanskaya V, Kumar A, et al. Direct induction of haematoendothelial programs in human pluripotent stem cells by transcriptional regulators. Nat Commun. 2014;5:4372.
97. Hoang T, Lambert JA, Martin R. SCL/TAL1 in hematopoiesis and cellular reprogramming. Curr Top Dev Biol. 2016;118:163-204.
98. Iwafuchi-Doi M, Zaret KS. Pioneer transcription factors in cell reprogramming. Genes Dev. 2014; 28(24):2679-2692.
99. Schuh AH, Tipping AJ, Clark AJ, et al. ETO-2 associates with SCL in erythroid cells and megakaryocytes and provides repressor functions in erythropoiesis. Mol Cell Biol. 2005; 25(23):10235-10250.
100. Stadhouders R, Cico A, Stephen T, et al. Control of developmentally primed erythroid genes by combinatorial co-repressor actions. Nat Commun. 2015;6:8893.
101. Tripic T, Deng W, Cheng Y, et al. SCL and associated proteins distinguish active from repressive GATA transcription factor complexes. Blood. 2009;113(10):2191-2201.
102. Juarez MA, Su F, Chun S, Kiel MJ, Lyons SE. Distinct roles for SCL in erythroid specification and maturation in zebrafish. J Biol Chem. 2005; 280(50):41636-41644.
103. Qian F, Zhen F, Xu J, Huang M, Li W, Wen Z. Distinct functions for different scl isoforms in zebrafish primitive and definitive hematopoiesis. PLoS Biol. 2007;5(5):e132.
104. Herblot S, Steff AM, Hugo P, Aplan PD, Hoang T. SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression. Nat Immunol. 2000;1(2):138-144.
105. Correia NC, Arcangeli ML, Pflumio F, Barata JT. Stem Cell Leukemia: how a TALented actor can go awry on the hematopoietic stage. Leukemia. 2016;30(10):1968-1978.
106. Ferrando AA, Herblot S, Palomero T, et al. Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia. Blood. 2004;103(5):1909-1911.
107. Gerby B, Tremblay CS, Tremblay M, et al. SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells. PLoS Genet. 2014;10(12): e1004768.
108. Aplan PD, Jones CA, Chervinsky DS, et al. An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. EMBO J. 1997; 16(9):2408-2419.
109. Larson RC, Lavenir I, Larson TA, et al. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J. 1996;15(5):1021-1027.
110. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004; 306(5694):269-271.
111. Tremblay M, Tremblay CS, Herblot S, et al. Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. Genes Dev. 2010;24(11):1093-1105.
112. Murre C. Helix-loop-helix proteins and lymphocyte development. Nat Immunol. 2005;6(11):1079-1086.
113. O’Neil J, Shank J, Cusson N, Murre C, Kelliher M. TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell. 2004;5(6):587-596.
114. Kusy S, Gerby B, Goardon N, et al. NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T cell acute lymphoblastic leukemia. J Exp Med. 2010; 207(10):2141-2156.
115. Palomero T, Odom DT, O’Neil J, et al. Transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia. Blood. 2006;108(3):986-992.
116. Sanda T, Lawton LN, Barrasa MI, et al. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell. 2012; 22(2):209-221.
117. O’Neil J, Billa M, Oikemus S, Kelliher M. The DNA binding activity of TAL-1 is not required to induce leukemia/lymphoma in mice. Oncogene. 2001;20(29):3897-3905.
118. Mansour MR, Abraham BJ, Anders L, et al. Oncogene regulation. An oncogenic superenhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014; 346(6215):1373-1377.
119. Mansour MR, Sanda T, Lawton LN, et al. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. J Exp Med. 2013;210(8):1545-1557.
120. Rowe JM. Optimal management of adults with ALL. Br J Haematol. 2009;144(4):468-483.
121. Kwiatkowski N, Zhang T, Rahl PB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014; 511(7511):616-620.
122. Lovén J, Hoke HA, Lin CY, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153(2):320-334.
123. Benyoucef A, Palii CG, Wang C, et al. UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia. Genes Dev. 2016;30(5):508-521.
124. Correia NC, Durinck K, Leite AP, et al. Novel TAL1 targets beyond protein-coding genes: identification of TAL1-regulated microRNAs in T-cell acute lymphoblastic leukemia. Leukemia. 2013;27(7):1603-1606.
125. Ferreira LG, Oliva G, Andricopulo AD. Protein-protein interaction inhibitors: advances in anticancer drug design. Expert Opin Drug Discov. 2016;11(10):957-968.
126. Appert A, Nam CH, Lobato N, et al. Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia. Cancer Res. 2009;69(11):4784-4790.
127. Tanaka T, Sewell H, Waters S, Phillips SE, Rabbitts TH. Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domain. J Biol Chem. 2011;286(5): 3707-3716.